Skip to main content
. 2019 May 1;11(1):e2019025. doi: 10.4084/MJHID.2019.025

Figure 3.

Figure 3

TKI switching patterns in SIMPLICITY in Italy (left hand panel) and the rest of the European SIMPLICITY population (excluding Italy; right hand panel) within the first 12 months of first-line TKI. No patients switched from the imatinib retrospective cohort in Italy. IM: imatinib; TKI: tyrosine kinase inhibitor.